The markets closed lower with the Dow dropping 65 points to 18,481 as sales of existing homes fell. Nasdaq tumbled 42 points to 5,217.
On the upside
Nymox Pharmaceutical (Nasdaq: NYMX) announced successful new study results from a long-term Phase 3 trial of the prostate cancer treatment fexapotide.
OraSure Technologies (Nasdaq: OSUR) won a contract for up to $16.6 million to advance rapid Zika tests.
Craft Brew Alliance (Nasdaq: BREW) and Anheuser-Busch amended and extended their master distribution agreement, entered a new contract brewing agreement and entered a new international distribution agreement.
On the downside
Falling gold and silver prices continued to weigh down shares of Hecla Mining (NYSE: HL).
Investors locked in profits on Arrowhead Pharmaceuticals (Nasdaq: ARWR).
Coeur Mining (NYSE: CDE) extended its losses as gold prices dropped.
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 2 on the NYSE and by nearly 2 to 1 on Nasdaq. The broader S&P 500 fell 11 points to 2,175. Bitcoin lost $2 to $578.
